Table 1. .
Baseline Characteristics of Participants in a Randomized Controlled Trial That Introduced Point-of-Care Diagnostic Tests to Guide Management of Outpatients With Febrile Illness, Conducted at 3 Clinical Sites in Uganda
| Characteristics | All Sites | Aduku (Kwania District) |
Nagongera (Tororo District) |
Kihihi (Kanungu District) |
||||
|---|---|---|---|---|---|---|---|---|
| Intervention | Control | Intervention | Control | Intervention | Control | Intervention | Control | |
| Total enrolled, n (%) | 1189 (49.5%) | 1211 (50.5%) | 401 (50.1%) | 399 (49.9%) | 398 (49.8%) | 402 (50.2%) | 390 (48.8%) | 410 (51.2%) |
| Patient age, n (%) | ||||||||
| <5 years | 364 (30.6%) | 377 (31.1%) | 116 (28.9%) | 67 (16.8%) | 158 (39.7%) | 198 (49.3%) | 90 (23.1%) | 112 (27.3%) |
| 5 to <10 years | 196 (16.5%) | 236 (19.5%) | 60 (15.0%) | 83 (20.8%) | 69 (17.3%) | 66 (16.4%) | 67 (17.2%) | 87 (21.2%) |
| ≥10 to <15 years | 102 (8.6%) | 111 (9.2%) | 33 (8.2%) | 43 (10.8%) | 23 (5.8%) | 21 (5.2%) | 46 (11.8%) | 47 (11.5%) |
| ≥15 years | 527 (44.3%) | 487 (40.2%) | 192 (47.9%) | 206 (51.6%) | 148 (37.2%) | 117 (29.1%) | 187 (48.0%) | 164 (40.0%) |
| Patient age, median (Q1, Q3), y | 11 (4, 23) | 9 (3, 20) | 13 (4, 23.5) | 15 (6, 21) | 6 (3, 22) | 5 (2, 18) | 13.5 (5, 23) | 10.5 (4, 20) |
| Patient gender, n (%) | ||||||||
| Female | 717 (60.3%) | 742 (61.3%) | 269 (67.1%) | 252 (63.2%) | 226 (56.8%) | 243 (60.5%) | 222 (56.9%) | 247 (60.2%) |
| Male | 472 (39.7%) | 469 (38.7%) | 132 (32.9%) | 147 (36.8%) | 172 (43.2%) | 159 (39.6%) | 168 (43.1%) | 163 (39.8%) |
| Date of enrollment, n (%) | ||||||||
| July–September 2020 | 19 (1.6%) | 21 (1.7%) | 7 (1.8%) | 7 (1.8%) | 12 (3.0%) | 14 (3.5%) | 0 (0.0%) | 0 (0.0%) |
| October–December 2020 | 258 (21.7%) | 256 (21.1%) | 88 (22.0%) | 84 (21.1%) | 88 (22.1%) | 85 (21.1%) | 82 (21.0%) | 87 (21.2%) |
| January–March 2021 | 326 (27.4%) | 340 (28.1%) | 114 (28.4%) | 120 (30.1%) | 101 (25.4%) | 100 (24.9%) | 111 (28.5%) | 120 (29.3%) |
| April–June 2021 | 389 (32.7%) | 375 (31.0%) | 136 (33.9%) | 124 (31.1%) | 131 (32.9%) | 132 (32.8%) | 122 (31.3%) | 119 (29.0%) |
| July–September 2021 | 197 (16.6%) | 219 (18.1%) | 56 (14.0%) | 64 (16.0%) | 66 (16.6%) | 71 (17.7%) | 75 (19.2%) | 84 (20.5%) |
| Respiratory vs nonrespiratory syndrome,a n (%) | ||||||||
| Respiratory | 648 (54.5%) | 421 (34.8%) | 206 (51.4%) | 179 (44.9%) | 255 (64.1%) | 183 (50.1%) | 187 (48.0%) | 59 (14.4%) |
| Nonrespiratory | 541 (45.5%) | 753 (62.2%) | 195 (48.6%) | 220 (55.1%) | 143 (35.9%) | 182 (49.9%) | 203 (52.1%) | 351 (85.6%) |
Abbreviation: Q, quarter.
As indicated by the managing clinician based on symptoms and signs, before performance of diagnostic tests. Note this information was not recorded on 37 patient forms in the Nagongera control arm.